Boston and ABC strains of mumps virus produced plaques approximately 1.0 mm in diameter in monolayers of BGM cells. The plaques were circular and either clear or target-like in form. Ricki strain virus produced plaques of similar size and form but, in addition, a red plaque was observed with this agent. The vaccine strain of mumps virus, Jeryl Lynn, produced minute clear plaques approximately 0.3 mm in diameter. Incorporation of diethylaminoethyl (DEAE)-dextran into the overlay medium did not affect the size difference between Jeryl Lynn plaques and those of the other strains. However plaques of the Jeryl Lynn and Ricki strains were more easily visualized when the overlay medium contained 400 ug/ml of DEAE-dextran.
Simultaneous titration by plaque formation and roller tube infectivity showed that these two methods were of equal sensitivity. Virus neutralization by antibody was demonstrated by plaque reduction. Rise in antibody titer was observed in sera from human and animal infection, human vaccination, and rabbit immunization.
The introduction of live virus mumps vaccine has stimulated virological studies on various mumps strains. Plaque characteristics have been very useful in studies of differences of virus strains and their attenuation. In addition, neutralization tests by plaque reduction also have provided an important means of measuring antibody response and investigating neutralization kinetics.
Frothingham and Granoff (5) first described mumps plaques in monolayers of chick embryo fibroblasts and HeLa cell. Gresser and Enders (6) later reported plaque formation by chick embryo-adapted virus in chick embryo fibroblast cell cultures and failure of this strain to produce plaques in human amnion cultures. They showed that a mumps virus strain adapted to growth in the latter cell culture system would produce plaques. Hotchin, Deibel, and Benson (7) developed a procedure in which foci of mumps virus growth were located by the hemadsorption technique. Recently, Ennis and co-workers (3) have described a plaque neutralization test for the detection of mumps antibody.
This report documents characteristics of plaque formation by various mumps virus strains as well as a plaque reduction neutralization procedure for assay of mumps antibody. The system used has been previously reported (1, 4 were made on plaques appearing 24 hr after staining. Plaques on day 2 were less than 0.5 mm in diameter. On day 4, 60% of plaques ranged between 0.8 and 1.0 mm, the remainder were smaller. On days 5 through 8, when maximum size was obtained, 80% of plaques were estimated to be 1.0 to 1.2 mm in diameter. Boston strain plaques on day 2 and day 3 were clear, circular unstained areas in the monolayers. Most plaques observed on subsequent days were also clear and circular. In addition a second type of plaque was observed, on approximately day 4. This plaque was target-like in appearance. It consisted of a central stained area surrounded by a peripheral clear zone. Target-like plaques on day 6 were approximately 30% of the population, whereas on day 7 there were fewer such plaques, even though the total number of plaques remained unchanged. This suggested that the target-like plaques changed to clear forms. Figure 1 shows the appearance of Boston strain plaques on day 6. Figure 2 shows the target-like plaques. Beyond day 7, in some experiments, streaking or tailing was observed.
ABC strain virus produced plaques which first were observed on day 2. The number increased to maximum level on day 4 and remained constant thereafter through day 9; 90 % of ABC plaques on day 2 were clear areas, less than 0.5 mm in diameter. Plaques on day 3 were somewhat larger, 30% being approximately 1.0 mm in diameter and the remainder smaller. Plaques on days 4, 5, 6, and 7 were large, 1.0 mm or greater in diameter. Targetlike plaques were seen in monolayers after day 3, but never exceeded 10% of the population (Fig.  3) .
Ricki strain plaques were first observed on day 2 (Fig. 4) . Low-power microscopic examination showed that target-like and clear plaques of Boston, ABC, and Ricki strains were syncytial in nature and that nuclei were aggregated in the center of the plaque. Plaques showing the target-like appearance had the neutral red stain concentrated about the nuclei in the syncytium. Red plaques did not appear to be syncytial.
The Enders strain did not produce plaques in BGM monolayers when inoculated in dilutions ranging from undiluted to 10-6. We were unable to detect replication of this agent through five passages in tube cultures of BGM cells when examined for CPE, HAD, or development of hemagglutinin when back-passaged in 8-day chick embryos.
Characteristics of Jeryl Lynn strain plaques. Similar experiments to those described above were Table 2 shows the results of an experiment in which Jeryl Lynn strain was observed for time of plaque appearance and count.
Jeryl Lynn plaques were first detected on day 3. The number increased on day 4 and remained constant through day 7. The plaques were minute clear areas, approximately 0.3 mm in diameter (Fig. 5) . No detectable change in size or form was noted throughout this or other experiments. Red plaques or target-like plaques have not been observed in Jeryl Lynn-infected monolayers.
Microscopic examination of Jeryl Lynn plaques showed the plaques were also syncytial in nature. Because of the small size of these plaques, it was often difficult to observe or count them under ordinary conditions of lighting. Plaques were best seen and counted when flasks were examined by transmitted light in a darkened room.
Effect of DEAE-dextran. In other plaque systems, the addition of polycations such as DEAEdextran or protamine has brought about reversal and enhancemeat of plaque size (13). Experments In these experiments various virus preparations were diluted in serial 10-fold increments and simultaneously inoculated into five roller tube cultures (0.1 ml per tube) and two plaque flasks (0.5 ml per flask). Plaque assays were carried out with 400 ,gg of DEAE-dextran added to the overlay medium. Table 4 shows the results of these experiments. Results indicated essentially equal sensitivity of these titration methods. The Jeryl Lynn strain was notably lower in titer than the other three strains by both methods. Infectivity titers of Jeryl Lynn strain obtained in this study were similar to those reported by Buynak and Hilleman (2) . These authors reported titers obtained in primary grivet monkey kidney cells.
Measurement of mumps-neutrlizing antibody. Neutralization of mumps virus infectivity by antibody was detected and quantitated by a plaque reduction test in BGM monolayers. Tests were carried out with rabbit sera, monkey sera, and human sera secured from clinical cases and from vaccinees. Figure 6 shows characteristic curves for neutralization tests of various sera against Boston strain virus. These curves relate the neutralizing capacity of antiserum dilutions to input infectivity. The data reflect the response in neutralizing antibody titers to natural and experimental infection and immunization with replicating and nonreplicating antigens.
The effect of DEAE-dextran in the overlay on plaque reduction by neutralizing antibodies was studied. A comparison of plaque reduction titers of a single serum, obtained in three experiments, is shown in Table 5 . The data suggest that incorporation of DEAE-dextran in the overlay tended to reduce variations in observed titers when the 50% reduction end point was used. No effect was noted when 80% reduction end points were used. Since DEAE-dextran improved the definition of plaques and did not affect the neutralization test, it was routinely used at a concentration of 400 ,ug/ml in overlay medium. Table 6 shows plaque reduction titers of serial bleedings from a monkey infected with mumps virus. The data reflect the response in neutralizing antibody titers in an experimentally infected animal. A significant titer of antibody was detected on the 10th day after infection. Antibody levels continued to rise through the 35th day. Plaque reduction tests demonstrated an increase in neutralizing antibody in a variety of situations. Antibody rises were detected in human sera secured from clinical cases of mumps virus infection or after vaccination with live virus vaccine, as well as in monkey sera obtained from experimentally infected animals. The tests also showed a response to nonreplicating viral antigen in the case of a rabbit immunized with V antigen.
